Liquidia Corp (NASDAQ:LQDA), a biopharmaceutical company with a market capitalization of $957 million, recently reported that Scott Moomaw, the company's Chief Commercial Officer, sold 546 shares of common stock on December 2, 2024. The shares were sold at $11.51 each, totaling $6,284, with the stock showing a strong 51.75% return over the past year. This transaction was carried out under a pre-established Rule 10b5-1 trading plan. InvestingPro analysis suggests the stock is currently overvalued, with analyst price targets ranging from $17 to $31.
Additionally, on November 30, 2024, Moomaw acquired 1,875 shares of Liquidia's common stock through the vesting of restricted stock units (RSUs). The RSUs were granted as part of a compensation package and did not involve any cash transaction. Following these transactions, Moomaw holds a total of 154,127 shares directly. For deeper insights into Liquidia's insider trading patterns and comprehensive financial analysis, subscribers can access the full InvestingPro Research Report, which provides expert analysis on this and 1,400+ other US stocks.
In other recent news, Liquidia Corporation announced key developments in its third quarter earnings call. The company reported a rise in Q3 revenue to $4.4 million, up from $3.7 million in the same quarter of the previous year, and a net loss of $23.2 million. Liquidia also highlighted its cash reserves of $204.4 million, preparing for the potential launch of YUTREPIA, an inhaled treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Furthermore, Liquidia is advancing the development of its next-generation product L606, with a pivotal study set to begin in the first half of 2025. The company has also expanded its partnership with Pharmosa for the development of a next-generation nebulizer, aiming to enhance drug delivery for L606.
These are recent developments, underlining Liquidia Corporation's focus on bringing innovative treatments to market for patients with pulmonary hypertension. The company's financial health and strategic partnerships suggest a robust approach to meeting the needs of patients and healthcare providers alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.